Top ▲

CYP2D6

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 1329

Nomenclature: CYP2D6

Family: CYP2 family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - - CYP2D6 cytochrome P450 family 2 subfamily D member 6
Previous and Unofficial Names Click here for help
Debrisoquine 4-hydroxylase | cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 8 pseudogene 2 | cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6 | cytochrome P450, subfamily 2D, polypeptide 6 | cytochrome P450, subfamily II (debrisoquine, sparteine, etc., -metabolising), polypeptide 7 pseudogene 2 | cytochrome P450, family 2, subfamily D, polypeptide 6
Database Links Click here for help
BRENDA
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
Pharos
SynPHARM
UniProtKB
Wikipedia
Enzyme Reaction Click here for help
EC Number: 1.14.14.1
Substrates and Reaction Kinetics Click here for help
Substrate Sp. Property Value Units Standard property Standard value Assay description Assay conditions Comments Reference
bufuralol N/A - - 1

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
ajmalicine Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibition 8.5 pKi 3
pKi 8.5 (Ki 3.3x10-9 M) [3]
TIQ-15 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.5 pIC50 2
pIC50 6.5 (IC50 3.2x10-7 M) [2]
compound 46c [PMID: 29350534] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 5.6 pIC50 2
pIC50 5.6 (IC50 2.61x10-6 M) [2]

References

Show »

1. Lindmark B, Lundahl A, Kanebratt KP, Andersson TB, Isin EM. (2018) Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s. Br. J. Pharmacol., 175 (11): 2116-2129. [PMID:29574682]

2. Miller EJ, Jecs E, Truax VM, Katzman BM, Tahirovic YA, Wilson RJ, Kuo KM, Kim MB, Nguyen HH, Saindane MT et al.. (2018) Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties. J. Med. Chem., 61 (3): 946-979. [PMID:29350534]

3. Strobl GR, von Kruedener S, Stöckigt J, Guengerich FP, Wolff T. (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J. Med. Chem., 36 (9): 1136-45. [PMID:8487254]

How to cite this page